Ovid Therapeutics (OVID) EBITDA Margin (2020 - 2025)
Ovid Therapeutics (OVID) reported EBITDA Margin of 1712.12% for Q4 2025, up 1239578.0% on a YoY basis from N/an in Q4 2024, and up 81.95% quarter-over-quarter from 9487.12% in Q3 2025.
Ovid Therapeutics (OVID) EBITDA Margin (2020 - 2025) Analysis & Trends
Ovid Therapeutics has reported EBITDA Margin for 6 years, with the latest figure at 1712.12% in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin rose 1239578.0% year-over-year to 1712.12%; the trailing twelve-month figure through Mar 2026 stood at 670.25% (up 973395.0% YoY), and the FY2025 full-year result was 585.2%, up 1034854.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 1712.12%, up from 9487.12% in the prior quarter.
- The five-year high for EBITDA Margin was 84.73% in Q1 2021, with the low at 115329.27% in Q3 2022.
- Historically, EBITDA Margin has averaged 17203.38% across 5 years, with a median of 11402.01% in 2023.
- The largest YoY upside for EBITDA Margin was 10429349 bps in 2023 against a maximum downside of 2075618 bps in 2023.
- Ovid Therapeutics' EBITDA Margin stood at 84.73% in 2021, then plunged by 31144 bps to 26302.75% in 2022, then jumped by 51 bps to 12808.45% in 2023, then declined by 10 bps to 14107.89% in 2024, then jumped by 88 bps to 1712.12% in 2025.
- The last three EBITDA Margin figures came in at 1712.12% (Q4 2025), 9487.12% (Q3 2025), and 80.88% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ovid Therapeutics | 311.83 Mn | 156.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,712.12% |
| Sep 30, 2025 | -9,487.12% |
| Jun 30, 2025 | -80.88% |
| Mar 31, 2025 | -9,653.85% |
| Dec 31, 2024 | -14,107.89% |
| Sep 30, 2024 | -7,645.09% |
| Jun 30, 2024 | -12,140.24% |
| Mar 31, 2024 | -11,768.24% |
| Dec 31, 2023 | -12,808.45% |
| Sep 30, 2023 | -11,035.78% |
| Jun 30, 2023 | -18,896.00% |
| Mar 31, 2023 | -22,563.64% |
| Dec 31, 2022 | -26,302.75% |
| Sep 30, 2022 | -115,329.27% |
| Mar 31, 2022 | -1,807.46% |
| Mar 31, 2021 | 84.73% |
| Dec 31, 2020 | -378.58% |
| Sep 30, 2020 | -237.25% |